Stocks TelegraphStocks Telegraph
Stock Ideas

ADAP Stock Performance and Key Statistics

NASDAQ : ADAP

Adaptimmune Therapeutics

$0.05
-0.0015-3.00%
At Close 4:00 PM
Not Actively Trading
64.51
BESG ScoreESG Rating

stock performance chart

ADAP Fundamental Analysis

Based on recent data, Adaptimmune Therapeutics plc (ADAP) shows an Average True Range (ATR) of 0.03 and an Enterprise Value of 98.61M. Its average trading volume over the past 3 months is N/A, indicating liquidity. These fundamental metrics provide insight into ADAP's underlying financial health and market activity.

ATR0.03
Enterprise Value98.61M
Avg Vol (3 Months)-
Avg Vol (10 Days)-

ADAP Technical Analysis Indicators

Adaptimmune Therapeutics plc (ADAP) technical indicators as of May 5, 2026: the SMA 20 is -57.94%, SMA 50 at -51.13%, and SMA 200 at -81.26%. The RSI 14 value is 37.5, suggesting its current momentum. These technical analysis signals help assess ADAP's price trends and potential future movements.

SMA 20-57.94%
SMA 50-51.13%
SMA 200-81.26%
RSI 1437.5

ADAP Stock Performance Overview

Adaptimmune Therapeutics plc (ADAP) stock performance overview as of May 5, 2026: The 52-week high is $0.358 (currently -94.16% below), and the 52-week low is $0.04 (currently 148.51% above). Over the past year, ADAP's performance is N/A, compared to the S&P 500's 16.14% change.

52-Week High0.3578
52-Week High Chg-94.16%
52-Week Low0.0403
52-Week Low Chg+148.51%
S&P 500 52-Week Chg16.14%

Adaptimmune Therapeutics plc (ADAP) Historical Stock Performance

According to market data, Adaptimmune Therapeutics plc (ADAP) stock's recent performance metrics show that over the last month, ADAP is -62.65%, with a Year-to-Date (YTD) performance of -89.81%. Over the past year, the stock has seen a N/A change. These figures summarize ADAP's price movements across various periods, reflecting its historical returns.

Period1 Week1 MonthQuarterHalf Year1 YearYTD
High0.09260.2750.2750.35780.3578N/A
Low0.04170.04170.04030.04030.0403N/A
Performance-6.95%-62.65%-47.66%-79.31%--89.81%

Industry Analysis and Valuation

According to current financial data, ADAP stock's P/E (TTM) ratio is -0.08, which compares to the S&P 500's P/E of 32.59. The sector median P/E is -1.22. Key valuation ratios for ADAP, including P/S (3.11), P/B (-0.18), and P/FCF (-0.55), offer insights into how the company is valued relative to its earnings, sales, book value, and free cash flow.

ValuationADAPSector MedianIndustry AvgS&P 500
P/E (TTM)-0.08-1.22-5.1232.59
P/S (TTM)3.113.69464.325.98
P/B (TTM)-0.180.28293.84.61
P/FCF (TTM)-0.55-6.26-445.4931.99

Frequently Asked Questions

How is ADAP price-to-earnings ratio currently?
ADAP has a current P/E ratio of -0.08
How are ADAP's price-to-sale and price-to-book ratios?
The ADAP stock has a trailing twelve month price-to sales (P/S) ratio of 3.11 while its price-to-book (P/B) value is -0.18.
Is Adaptimmune Therapeutics plc's price-to-cashflow ratio high or low?
ADAP's price-to-free-cashflow (P/FCF) ratio is -0.55, an indicator that is currently being trending upward.
What's current simple moving average (SMA) for ADAP?
Based on ADAP's recent bid, its distance from 20 days simple moving average is -57.94%. It is -51.13% apart from 50 days simple moving average, and it is -81.26% apart from 200 days simple moving average.
What is the 52-week price range for ADAP?
The 52-week high for ADAP is $0.86 which is -94.16% away from the current price level whereas the distance of that from the 52-week low of $0.02 stands at 148.51%.
An overview of ADAP's stock performance: how did it fare?
The performance of ADAP stock was not encouraging with most of its significant price indicators in red. Adaptimmune Therapeutics plc(NASDAQ: ADAP) shares have moved downward -3.00% or $0.00 in the latest trading session and have lost -89.81% year-to-date (YTD). The stock has lost nearly N/A over the past year. After moving -47.66% over the trailing 3-month period, the stock is -79.31% lower in the 6-month period. Looking at its performance over the shorter term, it'slost -6.95% a week and -62.65% a month.
What is ADAP's 14-day relative strength index (RSI)?
The current 14-day RSI for ADAP stock is 37.5. Investors and traders alike rely on the relative strength index, or RSI, as an oscillating indicator. In terms of values, the RSI operates within a range ranging from 0 to 100. A rising RSI line indicates strength in the shares. As the RSI line falls, the opposite occurs. It is possible to examine different time periods when using the RSI indicator. Shorter time frames can cause the RSI to be more volatile. Most traders pay close attention to the marks between 30 and 70 on the RSI scale. When the stock price moves over 70, it is often considered to be an indicator of overbought conditions. Dropping below 30 indicates oversold territory. These levels are often used by traders to forecast stock price reversals.
For ADAP, what is the average true range (ATR) for the past two weeks?
ATR stands for Average True Range, which may be useful when traders or investors are assessing technical inventory. Currently, Adaptimmune Therapeutics plc (ADAP) has a 14-day ATR of 0.03.
What is ADAP's current enterprise value?
After closing at $0.05 with 1.55B of its shares outstanding, the current enterprise value of ADAP is roughly 98.61M.
Over the past year, how has the stock price of ADAP changed?
Adaptimmune Therapeutics plc (NASDAQ: ADAP) is down N/A when it comes to the percentage price change over the past 52-weeks. The percentage price change came less than that of broader S&P 500 index that came at a fall of 16.14%. ADAP stock price is also down -89.81% on its value in year-to-date trading.
What is the average trading volume for ADAP shares?
The number outstanding shares of ADAP is 1.55B, and of these 98.89% shares are freely available for trading. On average, ADAP stock has traded - shares per day for the past 10 days. A total of 1.68M shares changed hands during the last trading session with the average session volume of 110.64M shares.
logo

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep

stockstelegraph

Don't have an account?

stockstelegraph

Don't have an account?

stockstelegraph

Already have an account?

stockstelegraph
Smart Screening Tools for Exceptional Returns
stockstelegraph

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!
stockstelegraph